URL : https://gphin.canada.ca/cepr/showarticle.jsp?docId=1006878083
ID : GPHN2020043000106

Date : 2020-04-30 04:04:00
Title : Glenmark gets nod to conduct clinical trials on Favipiravir Antiviral tablets on COVID-19 patients
Ariticle : 
India, April 30 -- Glenmark Pharmaceuticals has received approval from the Drug Controller General of India (DCGI), the regulator in India, to conduct clinical trials on Favipiravir Antiviral tablets on COVID-19 patients. The product is a generic version of Avigan of Fujifilm Toyama Chemical Co., Japan, a subsidiary of Fujifilm Corporation.
Favipiravir has demonstrated activity against influenza viruses and has been approved in Japan for the treatment of novel influenza virus infections. Recently in the past few months, post the outbreak of COVID-19, multiple clinical trials have been initiated on COVID-19 patients in China, Japan and in the US.
Glenmark Pharmaceuticals is a global pharmaceutical company. The company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW).
Published by HT Digital Content Services with permission from Accord Fintech.